Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Core23 BioBank is a private healthcare company focused on collecting, processing, cryopreserving, storing, and distributing umbilical cord blood and cord tissue for potential therapeutic use. The company operates as a hybrid public/private cord blood bank, offering families the option to bank newborn stem cell material for possible future use by the child or related family members. Its business is service-based rather than a traditional drug-development biotech model, with an emphasis on stem cell preservation and regenerative medicine support. Core23 appears to serve customers across the United States from its Missouri operations and markets itself around cord blood, cord tissue, and related stem cell banking services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Core23 BioBank.